Endocrine Journal
Online ISSN : 1348-4540
Print ISSN : 0918-8959
ISSN-L : 0918-8959
Rectus femoris ultrasonography as an adjunctive tool to evaluate residual muscle impairment in patients with controlled Cushing’s syndrome and acromegaly
Luciana Martel-Duguech, Helena Bascuñana, Susan M. Webb, Elena Valassi
Author information
JOURNAL OPEN ACCESS Advance online publication
Supplementary material

Article ID: EJ26-0221

Details
Abstract

Muscle impairment, characterized by reduced muscle quality and functional performance, may persist in patients with Cushing’s syndrome (CS) in remission and acromegaly (ACRO) after long-term biochemical control. This study evaluated whether rectus femoris ultrasonography (US), using standardized thickness and volume measurements and semi-quantitative Heckmatt echogenicity grading, identifies residual muscle quality abnormalities in these patients and whether US findings relate to magnetic resonance imaging (MRI)-derived fat fraction (FF), functional performance, and patient-reported outcomes. We studied 36 women with CS in remission, 36 patients with long-term controlled ACRO, and 64 unique healthy controls used for disease-specific matched comparisons. Rectus femoris and vastus intermedius US assessed muscle size and echogenicity at mid-thigh and distal-third sites. MRI FF was measured using a 2-point Dixon sequence. Physical performance was assessed by gait speed, timed up-and-go, 30-second chair-stand, and handgrip strength tests. Quality of life (QoL) was assessed using CushingQoL, AcroQoL, and the 36-Item Short Form Health Survey (SF-36). Rectus femoris echogenicity was higher in both patient groups than in matched controls despite similar US muscle size. Higher echogenicity correlated with MRI-derived thigh FF and with selected measures of poorer physical performance. Associations with QoL were exploratory and were strongest for physical functioning-related domains, although broader disease-related and psychosocial contributors cannot be excluded. These findings support muscle US as a feasible adjunct to biochemical follow-up and MRI for identifying residual myopathy in controlled pituitary disease. Longitudinal and multicenter studies using standardized quantitative US protocols are needed to define reproducibility and clinical thresholds.

Fullsize Image
Content from these authors
© The Japan Endocrine Society

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Next article
feedback
Top